Motor cortex excitability in Alzheimer's disease: A transcranial magnetic stimulation follow-up study

Neuroscience Letters

Volumn 492, Issue 2, 2011, Pages 94-98

  Ferreri, Florinda ^a,b   Pasqualetti, Patrizio ^c,d   Määttä, Sara ^b   Ponzo, David ^a,b,c   Guerra, Andrea ^a   Bressi, Federica ^a   Chiovenda, Paola ^a,c   del Duca, Marco ^a   Giambattistelli, Federica ^a   Ursini, Francesca ^a   Tombini, Mario ^a   Vernieri, Fabrizio ^a   Rossini, Paolo Maria ^a,b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c FATEBENEFRATELLI HOSPITAL   (Italy)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease; Transcranial magnetic stimulation

Indexed keywords

DONEPEZIL;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; FEMALE; HUMAN; LONG TERM CARE; MALE; MOTOR CORTEX; NERVE EXCITABILITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDANS; MALE; MIDDLE AGED; MOTOR CORTEX; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 79952068849     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.01.064     Document Type: Article

References (52)

1. Alagona G., Bella R., Ferri R., Costanzo E., Pennisi G. Transcranial magnetic stimulation in Alzheimer disease: motor cortex excitability and cognitive severity. Neurosci. Lett. 2001, 314(1-2):57-60.
2. Babiloni C., Babiloni F., Carducci F., Zanetti O., Rossini P.M. Movement-related electroencephalographic reactivity in Alzheimer disease. Neuroimage 2000, 12(2):139-146.
3. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217:408-417.
4. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev. 2006, 25(1):CD005593.
5. Bowen D.M., Smith C.B., White P., Davison A.N. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976, 99:459-496.
6. Bullock R., Bergman H., Gambina G., He Y., Nagel J., Lane R. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Curr. Med. Res. Opin. 2006, 22(3):483-494.
7. Burke W.J., Houston M.J., Boust S.J., Roccaforte W.H. Use of the geriatric depression scale in dementia of the Alzheimer type. J. Am. Geriatr. Soc. 1989, 37(9):856-860.
8. Caltagirone C., Gainotti G., Masullo C., Miceli G. Validity of some neuropsychological tests in the mental deterioration. Acta Psychiatr. Scand. 1979, 60(July (1)):50-56.
9. Charpentier P., Lavenu I., Pasquier F., Steinling M. Alzheimer's disease and frontotemporal dementia are differentiated by discriminant analysis applied to (99m)Tc HmPAO SPECT data. J. Neurol. Neurosurg. Psychiatry 2000, 69:661-663.
10. Coyle J.T., Price D.L., DeLong M.R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983, 219:1184-1190.
11. Davidsson P., Blennow K., Minthon L., Hesse C. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neurosci. Lett. 2001, 300(3):157-160.
12. De Carvalho M., De Mendoca A., Garcia C., Luís M.L. Magnetic stimulation in Alzheimer's disease. J. Neurol. 1997, 244:304-307.
13. De Sevilla D.F., Cabezas C., De Prada A.N., Sánchez-Jiménez A., Buño W. Selective muscarinic regulation of functional glutamatergic Schaffer collateral synapses in rat CA1 pyramidal neurons. J. Physiol. 2002, 545:51-63.
14. Di Lazzaro V., Oliviero A., Tonali P.A., Saturno E., Pilato F., Masullo C., Rothwell J.C. Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation. Neurology 2002, 59(3):392-397.
15. Di Lazzaro V., Oliviero A., Pilato F., Dileone M., Tonali P.A. Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer's disease: evidence of impaired glutamatergic neurotransmission?. Ann. Neurol. 2003, 53(June (6)):824.
16. Di Lazzaro V., Oliviero A., Pilato F., Ghirlanda S., Ranieri F., Gainotti G., Tonali P. Neurophysiological predictors of long term response to AChE inhibitors in AD patients. J. Neurol. Neurosurg. Psychiatry 2005, 76:1064-1069.
17. Ferreri F., Pauri F., Pasqualetti P., Fini R., Dal Forno G., Rossini P.M. Motor cortex excitability in Alzheimer's disease: a transcranial magnetic stimulation study. Ann. Neurol. 2003 Jan, 53(1):102-108.
18. Fisher A. Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists. Jpn. J. Pharmacol. 2000, 84(2):101-112.
19. Folstein M.F., Folstein S.E., McHugh P.R. "Mini Mental State": a practical method for grading the cognitive state of patient for the clinician. J. Psychiatr. Res. 1975, 12(3):189-198.
20. Francis P.T., Sims N.R., Bowen D.M. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives. J. Neurochem. 1993, 60(5):1589-1604.
21. Francis P.T., Palmer A.M., Snape M., Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 1999, 66(2):137-147.
22. Gambina G., Moretto G., Corbo R.M. Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine. Am. J. Med. Genet. 2009, 150B(4):502-507.
23. Han L., Cole M., Bellavance F., McCusker J., Primeau F. Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis. Int. Psychogeriatr. 2000, 12(2):231-247.
24. Hess G., Krawcyk R. Cholinergic modulation of synaptic transmission in horizontal connections of rat motor cortex. Acta Neurobiol. Exp. 1996, 56(4):863-872.
25. Hyman B.T., Van Hoesen G.W., Damasio A.R. Alzheimer's disease: glutamate depletion in the hippocampal perforant pathway zone. Ann. Neurol. 1987, 22(1):37-40.
26. IQWiG Working Papers, Memantine in Alzheimer's Disease: (Working Paper as a Supplement to the Final Report A05-19C: Memantine in Alzheimer's Disease), Institute for Quality and Efficiency in Health Care Dillenburger Str. 27 51105 Cologne Germany, 02.08.2010 (). http://www.iqwig.de/index.404.html.
27. Jones R.W., Schwam E., Wilkinson D., Feldman H.H., Zhang R., Albert K., Schindler R Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil. Alzheimer Dis. Assoc. Disord. 2009, 23(4):357-364.
28. Krall W.J., Sramek J.J., Cutler NR Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. Ann. Pharmacother. 1999, 33(4):441-450.
29. Lawton M.P., Brody E.M. Assessment of older people; self-maintaining and instrumental activities of daily living. Gerontologist 1969, 9(3):179-186.
30. Liepert J., Bar K., Meske U., Weiller C. Motor cortex disinhibition in Alzheimer's disease. Clin. Neurophhysiol. 2001, 112(8):1436-1441.
31. Lowe S.L., Bowen D.M., Francis P.T., Neary D. Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease. Neuroscience 1990, 38(3):571-577.
32. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34(7):939-944.
33. McShane R., Areosa Sastre A., Minakaran N. Memantine for dementia. Cochrane Database Syst. Rev. 2006, 19(2):CD003154.
34. Mesulam M., Carson K., Price B., Geula C. Cholinesterases in the amyloid angiopathy of Alzheimer's disease. Ann. Neurol. 1992, 31:565-569.
35. + current in rat neocortical pyramidal neurons. J. Neurophysiol. 1998, 79(3):1579-1582.
36. Mohs R.C., Doody R.S., Morris J.C., Ieni J.R., Rogers S.L., Perdomo C.A., Pratt R.D. Study Group A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001, 57(10):1942. "312" Study Group.
37. Nagga K., Bogdanovic N., Marcusson J. GABA transporters (GAT-1) in Alzheimer's disease. J. Neural Transm. 1999, 106:1141-1149.
38. Nobili F., Koulibaly M., Vitali P., Pupi A., Robert P.H., Rodriguez G., Darcourt J. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. J. Nucl. Med. 2002, 43(8):983-990.
39. Oyama M., Senda M., Katayama Y. Preserved benzodiazepine receptors in Alzheimer's disease measured with C-11 flumazenil PET and I-123 iomazenil STECT in comparison with CBF. Ann. Nucl. Med. 1999, 13:309-315.
40. Pennisi G., Alagona G., Ferri R., Pappalardo A., Bella R. Motor cortex excitability in Alzheimer disease: one year follow-up study. Neurosci. Lett. 2002, 329(3):293.
41. Pepin J.L., Bogacz D., De Pasqua V., Delwaide P. J. Motor cortex inhibition is not impaired in patients with Alzheimer disease: evidence from paired transcranical magnetic stimulation. J. Neurol. Sci. 1999, 170(2):119-123.
42. Qaseem A., Snow V., Cross J.T., Adelman A., Santaguida P., Owens D.K. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann. Intern. Med. 2008, 148(5):370-378.
43. Rossini P.M., Barker A.T., Belardelli A., Caramia M.D., Caruso G., Cracco R.Q., Dimitrijevic M.R., Hallett M., Katayama Y., Lucking C.H. Non-invasive electrical and magnetic stimulation of the brain, spinal cord and roots: basic principles and procedures for routine clinical application. Report of an IFCN committee. Electroencephalogr. Clin. Neurophysiol. 1994, 91(2):79-92.
44. Rossini P.M., Calautti C., Pauri F., Baron J.C. Post-stroke plastic reorganisation in the adult brain. Lancet Neurol. 2003, 2(8):493-502.
45. Rothwell J.C., Hallett M., Berardelli A., Eisen A., Rossini P., Paulus W. Magnetic stimulation: motor evoked potentials. The International Federation of Clinical Neurophysiology. Electroencephalogr. Clin. Neurophysiol. Suppl. 1999, 52:97-103.
46. Sanes J.N., Donoghue J.P. Plasticity and primary motor cortex. Annu. Rev. Neurosci. 2000, 23:393-415.
47. Sillito M. The Cholinergic Neuromodulatory System: An Evaluation of Its Functional Roles 1993, Elsevier Science Publishers, pp. 371-378.
48. Suva D., Favre I., Kraftsik R., Lobrinus A., Miklossy J. Primary motor cortex involvement in Alzheimer disease. J. Neuropathol. Exp. Neurol. 1999, 58(11):125-1134.
49. Tariot PN Cognitive function in Alzheimer disease: how effective are current treatments?. Alzheimer Dis. Assoc. Disord. 2001, 151:S26-33.
50. Whitehouse P.J., Price D.L., Coyle J.T., Delon M.R. Alzheimer's disease and senile dementia: loss of neurones in basal forebrain. Science 1982, 215:1237-1239.
51. Winblad B., Engedal K., Haglund A., Subbiah P. 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001, 57(3):489-495. Donepezil Nordic Study Group.
52. Winkler J., Thal L., Gage F., Fisher L. Cholinergic strategies for Alzheimer's disease. J. Mol. Med. 1998, 76:555-567.